Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement

LymphoCide Y-90 (epratuzumab Y-90) - Gilead

sequential different B cell antigen-targeted CAR T-cell therapy - Beijing Boren Hospital

https://eventpilot.us/web/page.php?page=Session&project=ASH21&id=146302

Ying Liu, MD1; Biping Deng, PhD2; Bo Hu1; Wenqun Zhang, MD1; Qing Zhu1; Yang Liu1; Shan Wang1; Pei Zhang1; Junhan Yang1; Qinlong Zheng3; Xinjian Yu3; Zifen Gao4; Chunju Zhou5; Wei Han6; Alex Hong Chang, MD7; Yonghong Zhang, MD1

Nov 5, 2021